BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 28476883)

  • 1. The long non-coding RNA HOTAIR enhances pancreatic cancer resistance to TNF-related apoptosis-inducing ligand.
    Yang SZ; Xu F; Zhou T; Zhao X; McDonald JM; Chen Y
    J Biol Chem; 2017 Jun; 292(25):10390-10397. PubMed ID: 28476883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HOTAIR-mediated reciprocal regulation of EZH2 and DNMT1 contribute to polyphyllin I-inhibited growth of castration-resistant prostate cancer cells in vitro and in vivo.
    Xiang S; Zou P; Tang Q; Zheng F; Wu J; Chen Z; Hann SS
    Biochim Biophys Acta Gen Subj; 2018 Mar; 1862(3):589-599. PubMed ID: 29221985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The herbal compound cryptotanshinone restores sensitivity in cancer cells that are resistant to the tumor necrosis factor-related apoptosis-inducing ligand.
    Tse AK; Chow KY; Cao HH; Cheng CY; Kwan HY; Yu H; Zhu GY; Wu YC; Fong WF; Yu ZL
    J Biol Chem; 2013 Oct; 288(41):29923-33. PubMed ID: 23986445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.
    Yu R; Albarenque SM; Cool RH; Quax WJ; Mohr A; Zwacka RM
    Cancer Biol Ther; 2014; 15(12):1658-66. PubMed ID: 25482930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-gout agent allopurinol exerts cytotoxicity to human hormone-refractory prostate cancer cells in combination with tumor necrosis factor-related apoptosis-inducing ligand.
    Yasuda T; Yoshida T; Goda AE; Horinaka M; Yano K; Shiraishi T; Wakada M; Mizutani Y; Miki T; Sakai T
    Mol Cancer Res; 2008 Dec; 6(12):1852-60. PubMed ID: 19074830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metformin Causes G1-Phase Arrest via Down-Regulation of MiR-221 and Enhances TRAIL Sensitivity through DR5 Up-Regulation in Pancreatic Cancer Cells.
    Tanaka R; Tomosugi M; Horinaka M; Sowa Y; Sakai T
    PLoS One; 2015; 10(5):e0125779. PubMed ID: 25955843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipocalin 2 inversely regulates TRAIL sensitivity through p38 MAPK-mediated DR5 regulation in colorectal cancer.
    Kim SL; Min IS; Park YR; Lee ST; Kim SW
    Int J Oncol; 2018 Dec; 53(6):2789-2799. PubMed ID: 30221676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chaetospirolactone reverses the apoptotic resistance towards TRAIL in pancreatic cancer.
    Hu W; Jia X; Gao Y; Zhang Q
    Biochem Biophys Res Commun; 2018 Jan; 495(1):621-628. PubMed ID: 29107694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Death receptor 5 is activated by fucosylation in colon cancer cells.
    Zhang B; van Roosmalen IAM; Reis CR; Setroikromo R; Quax WJ
    FEBS J; 2019 Feb; 286(3):555-571. PubMed ID: 30589515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of Yin Yang 1-dependent repressor activity of DR5 transcription and expression by the novel proteasome inhibitor NPI-0052 contributes to its TRAIL-enhanced apoptosis in cancer cells.
    Baritaki S; Suzuki E; Umezawa K; Spandidos DA; Berenson J; Daniels TR; Penichet ML; Jazirehi AR; Palladino M; Bonavida B
    J Immunol; 2008 May; 180(9):6199-210. PubMed ID: 18424742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel TRAIL mutant-TRAIL-Mu3 enhances the antitumor effects by the increased affinity and the up-expression of DR5 in pancreatic cancer.
    Huang M; Zhu H; Yi C; Yan J; Wei L; Yang X; Chen S; Huang Y
    Cancer Chemother Pharmacol; 2018 Nov; 82(5):829-838. PubMed ID: 30167846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL.
    Hari Y; Harashima N; Tajima Y; Harada M
    Oncotarget; 2015 Dec; 6(39):41902-15. PubMed ID: 26506422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HuR Contributes to TRAIL Resistance by Restricting Death Receptor 4 Expression in Pancreatic Cancer Cells.
    Romeo C; Weber MC; Zarei M; DeCicco D; Chand SN; Lobo AD; Winter JM; Sawicki JA; Sachs JN; Meisner-Kober N; Yeo CJ; Vadigepalli R; Tykocinski ML; Brody JR
    Mol Cancer Res; 2016 Jul; 14(7):599-611. PubMed ID: 27053682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TRAIL induces apoptosis but not necroptosis in colorectal and pancreatic cancer cells preferentially via the TRAIL-R2/DR5 receptor.
    Nahacka Z; Svadlenka J; Peterka M; Ksandrova M; Benesova S; Neuzil J; Andera L
    Biochim Biophys Acta Mol Cell Res; 2018 Mar; 1865(3):522-531. PubMed ID: 29278689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIF-2α dictates the susceptibility of pancreatic cancer cells to TRAIL by regulating survivin expression.
    Harashima N; Takenaga K; Akimoto M; Harada M
    Oncotarget; 2017 Jun; 8(26):42887-42900. PubMed ID: 28476028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tanshinone IIA induces TRAIL sensitization of human lung cancer cells through selective ER stress induction.
    Kim EO; Kang SE; Im CR; Lee JH; Ahn KS; Yang WM; Um JY; Lee SG; Yun M
    Int J Oncol; 2016 May; 48(5):2205-12. PubMed ID: 26983803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-Thermal Plasma Couples Oxidative Stress to TRAIL Sensitization through DR5 Upregulation.
    Hwang SY; Nguyen NH; Kim TJ; Lee Y; Kang MA; Lee JS
    Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32722598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of RIP and c-FLIP enhances TRAIL-induced apoptosis in pancreatic cancer cells.
    Wang P; Zhang J; Bellail A; Jiang W; Hugh J; Kneteman NM; Hao C
    Cell Signal; 2007 Nov; 19(11):2237-46. PubMed ID: 17693058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects and expression of TRAIL and its apoptosis-promoting receptors in human pancreatic cancer.
    Ozawa F; Friess H; Kleeff J; Xu ZW; Zimmermann A; Sheikh MS; Büchler MW
    Cancer Lett; 2001 Feb; 163(1):71-81. PubMed ID: 11163110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Understanding of tolerance in TRAIL-induced apoptosis and cancelation of its machinery by α-mangostin, a xanthone derivative.
    Kumazaki M; Shinohara H; Taniguchi K; Ueda H; Nishi M; Ryo A; Akao Y
    Oncotarget; 2015 Sep; 6(28):25828-42. PubMed ID: 26304927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.